About this episode

Dr. Carla Casulo discusses the latest lymphoma research and treatment strategies presented at ASH 2025.

BloodCancerTalks: ASH 2025 Lymphoma Roundup Guest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester Abstracts Discussed Follicular Lymphoma EPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL Theme: Bispecific antibody combinations in R/R FL; comparing to other approaches Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients MorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible EPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients R-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients Theme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients DLBCL - First-Line Treatment SMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen) FrontMIND - Tafasitamab-lenalidomide added to R-CHOP Theme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL DLBCL - Relapsed/Refractory DALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients Theme: Expanding…

People in this episode

Guest: Dr. Carla Casulo

Topics covered

• Lymphoma treatment
• Bispecific antibodies
• Elderly patient care
• Chemotherapy-free approaches
• CAR-T therapy
• Long-term outcomes in Hodgkin lymphoma

Keywords

• Lymphoma
• Epcoritamab
• CAR-T therapy
• Nivolumab
• Hodgkin lymphoma
• Elderly patients
• Chemotherapy-free treatment

Mentioned in this episode

Organizations: Wilmot Cancer Centre, University of Rochester

Products: Epcoritamab, lenalidomide, rituximab, Mosunetuzumab, R-CHOP, Nivolumab, brentuximab, Tafasitamab, acalabrutinib, zamto-cel

More episodes of Blood Cancer Talks

• Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez · February 27, 2026 · 57 min
• Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa · January 2, 2026 · 46 min
• Episode 67. Management of CMV in Hematologic Malignancies · November 23, 2025 · 40 min
• Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza · October 15, 2025 · 52 min
• Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain · September 24, 2025 · 53 min
• Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson · August 20, 2025 · 43 min

Explore listener stats, chart rankings, contacts and more on the Blood Cancer Talks podcast page.